BFRI: SEC Form 25-NSE filed by Biofrontera Inc.
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for BFRI
Across the 24 sessions after earlier BFRI headlines, the stock closed higher 12 times and lower 12 times, with a median move of 3.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | BFRI | SPY |
|---|---|---|---|
| Oct 8, 2026 | Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body | -1.8% | -0.4% |
| Sep 14, 2026 | Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma | -12.3% | -0.4% |
| Aug 13, 2026 | Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth | +0.8% | +0.7% |
| Aug 6, 2026 | Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026 | +0.8% | -0.2% |
| May 21, 2026 | Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 | -3.4% | +0.2% |
| May 19, 2026 | Biofrontera Inc. downgraded by The Benchmark Company with a new price target | +1.4% | -0.7% |
Quantisnow market dataNASDAQ
BFRI
Biofrontera Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Get push alerts for BFRI
Full BFRI profile on Quantisnow Follow BFRI and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time